Highlights

Highlights

Subject to update: 

  • CAR T cell therapies in hematological malignancies
  • CAR and TCR targets
  • Engineered T cell therapy for solid tumours
  • Non-viral vectors and transposons
  • Allogeneic/universal donor cells
  • Rare, autoimmune and infectious diseases as cell therapy targets
  • New approaches in lymphocyte engineering
  • Regulatory Perspectives and Requirements in Advanced Therapies